Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Merimepodib (VX-497) is a novel noncompetitive inhibitor of Inosine monophosphate dehydrogenase(IMPDH).
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 39.00 | |
5 mg | In stock | $ 91.00 | |
10 mg | In stock | $ 163.00 | |
25 mg | In stock | $ 297.00 | |
50 mg | In stock | $ 538.00 | |
100 mg | In stock | $ 777.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 90.00 |
Description | Merimepodib (VX-497) is a novel noncompetitive inhibitor of Inosine monophosphate dehydrogenase(IMPDH). |
In vitro | VX-497 has antiproliferative effect on lymphoid and keratinocyte cells. VX-497 (MW 452.5) is orally bioavailable and inhibits the proliferation of primary human, mouse, rat, and dog lymphocytes at concentrations of approximately 100 nM. The antiproliferative effect of VX-497 in cells is reversed within 48 h of its removal[1]. VX-497 has intermediate antiviral activity against a second group of viruses, which includes HSV-1, parainfluenza-3 virus, BVDV, VEEV, and dengue virus, with IC50s ranging from 6 to 19 μM. VX-497 is 100-fold more potent, with an IC50 of 380 nM and a corresponding CC50 of 5.2 μM, for a therapeutic index of 14. The antiviral activity of VX-497 in HepG2.2.2.15 cells is reversed threefold by the addition of guanosine[2]. |
In vivo | Administering VX-497 orally attenuates the primary IgM antibody response in mice in a dose-dependent manner, achieving an effective dose 50 (ED50) between 30-35 mg/kg. Both single and twice-daily dosing of VX-497 are comparably effective in reducing immune activation in this model[1]. In models of graft-versus-host disease (GVHD) involving allografted F1 mice, the untreated group displayed disease development, whereas VX-497 treatment significantly ameliorated disease symptoms. Specifically, VX-497 treatment decreased the spleen weight increase from 2.9-fold in untreated allografted mice to 1.6-fold, and reduced serum interferon-gamma (IFN-gamma) levels from a 54-fold increase in the control group to a 7.4-fold increase in treated mice[3]. |
Cell Research | The murine fibroblast L929 cell line is cultured in Eagle minimal essential medium supplemented with 10% fetal bovine serum, nonessential amino acids, 50 U of penicillin per mL, 50 μg of streptomycin per mL, and 2 mM?l-glutamine. EMCV is infected at 500 PFU/107?L929 cells. Cells are left untreated or are treated with different concentrations of murine IFN-α alone, VX-497 alone, or combinations thereof. |
Synonyms | VX-497, VI-21497 |
Molecular Weight | 452.46 |
Formula | C23H24N4O6 |
CAS No. | 198821-22-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 31 mg/mL (68.51 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Merimepodib 198821-22-6 Immunology/Inflammation Metabolism Microbiology/Virology Proteases/Proteasome Dehydrogenase HCV Protease Antiviral HBV HCV Inhibitor Hepatitis C virus Hepatitis B virus VX497 VX 497 inhibit MMPD VI 21497 VX-497 VI-21497 VI21497 inhibitor